Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer (PRIMUS)
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Sponsor: HiberCell, Inc.
Terminated
Due to enrollment challenges resulting from changing treatment patterns in the use of cetuximab, the study has been terminated. No patients remain on study.
Other terminated trials from HiberCell, Inc.
- Squamous Cell Carcinoma of the Head and Neck · Phase PHASE2 · Apr 2018
- Pancreatic Cancer · Phase PHASE1 · Apr 2015
More terminations from HiberCell, Inc.
Other Colorectal Cancer trials with similar outcome
A PHASE3 clinical study on Colorectal Cancer, this trial is terminated or withdrawn. The trial is conducted by HiberCell, Inc. and has accumulated 11 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Oct 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE3
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Apr 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- HiberCell, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .